From the Guidelines
Depakote and generic valproic acid are essentially the same medication, with the primary difference being the formulation, as Depakote contains divalproex sodium, while generic valproic acid contains the same active ingredient but may have different inactive ingredients. The therapeutic effects, dosing, and side effect profiles are generally equivalent between the two, as both work by increasing levels of gamma-aminobutyric acid (GABA) in the brain, which helps reduce excessive neuronal activity 1. Some patients may notice subtle differences in how they respond to the brand versus generic versions due to variations in bioavailability, which can be affected by the inactive ingredients. If switching between brand and generic forms, patients should monitor for any changes in effectiveness or side effects and discuss these with their healthcare provider. Cost is often a significant difference, with generic valproic acid typically being less expensive than brand-name Depakote, making it more accessible for long-term treatment. Key points to consider when choosing between Depakote and generic valproic acid include:
- Efficacy: Both Depakote and generic valproic acid have been shown to be effective in treating seizures, bipolar disorder, and migraines 1.
- Safety: The side effect profiles of Depakote and generic valproic acid are generally equivalent, with common side effects including dizziness, nausea, and headache 1.
- Cost: Generic valproic acid is often less expensive than brand-name Depakote, making it a more accessible option for long-term treatment. In terms of administration, valproate can be given intravenously at a dose of up to 30 mg/kg at a rate of 10 mg/kg/min, with potential adverse effects including dizziness, thrombocytopenia, liver toxicity, and hyperammonemia 1. Overall, the choice between Depakote and generic valproic acid should be based on individual patient needs and circumstances, taking into account factors such as efficacy, safety, and cost.
From the FDA Drug Label
Valproic acid is administered orally. Valproic acid is indicated as monotherapy and adjunctive therapy in complex partial seizures in adults and pediatric patients down to the age of 10 years, and in simple and complex absence seizures. Valproic acid is indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures.
The main difference between Depakote (valproic acid) and generic valproic acid is the brand name versus generic name.
- Depakote is a brand name for valproic acid.
- Valproic acid is the generic name for the same medication. Both Depakote and generic valproic acid are used for the same indications, including complex partial seizures and simple and complex absence seizures 2 2. There is no difference in the dosage and administration of Depakote and generic valproic acid, as both are administered orally and have the same recommended dosages 2.
From the Research
Difference between Depakote and Valproic Acid
- Depakote is a brand name for the medication divalproex sodium, which is a compound containing valproic acid 3.
- Valproic acid, also known as Depakene, is the generic form of the medication 4.
- Both Depakote and valproic acid are used to treat various types of seizures, including complex partial seizures and secondarily generalized tonic-clonic seizures 5.
Bioavailability and Formulation
- A study compared the bioavailability of Depakote Sprinkle capsules with valproic acid syrup and found that the extent of absorption was similar, but absorption was slower with the sprinkle formulation 3.
- The sprinkle formulation was preferred by patients and parents due to its ease of administration and improved palatability 3.
Side Effects
- Valproic acid has been associated with various side effects, including weight gain, hair loss, tremor, and rash 5, 4, 6.
- Depakote has also been reported to cause similar side effects, including weight gain, hair loss, and tremor 3.
- Valproate-associated coagulopathies, such as thrombocytopenia and decreased factor VII levels, have been reported in children during short-term treatment 7.